Ultragenyx awaits two potential FDA approvals and vital data readouts this year, even though it continues to trade at a significant discount to its historical EV/sales multiple. The recent acquisitions have made its pipeline even more diverse as the company turns to less-rare diseases to accelerate the revenue […]